tbuckley/cabot-search huggingface dataset:
Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
Authors: Markus Fusser, Anders Øverbye, Abhilash D. Pandya, Ýrr Mørch, Sven Even Borgos, Wanja Kildal, Sofie Snipstad, Einar Sulheim, Karianne Giller Fleten, Hanne Arenberg Askautrud, Olav Engebraaten, Kjersti Flatmark, Tore Geir Iversen, Kirsten Sandvig, Tore Skotland, Gunhild M. Mælandsmo
Journal: Journal of Controlled Release (2018)

The effect of poly(2-ethyl-butyl cyanoacrylate) nanoparticles containing the cytotoxic drug cabazitaxel was studied in three breast cancer cell lines and one basal-like patient-derived xenograft model grown in the mammary fat pad of immunodeficient mice. Nanoparticle-encapsulated cabazitaxel had a much better efficacy than similar concentrations of free drug in the basal-like patient-derived xenograft and resulted in complete remission of 6 out of 8 tumors, whereas free drug gave complete remission only with 2 out of 9 tumors. To investigate the different efficacies obtained with nanoparticle-encapsulated versus free cabazitaxel, mass spectrometry quantification of cabazitaxel was performed in mice plasma and selected tissue samples. Nanoparticle-encapsulated drug had a longer circulation time in blood. There was approximately a three times higher drug concentration in tumor tissue 24 h after injection, and two times higher 96 h after injection of nanoparticles with drug compared to the free drug. The tissue biodistribution obtained after 24 h using mass spectrometry analyses correlates well with biodistribution data obtained using IVIS® Spectrum in vivo imaging of nanoparticles labeled with the fluorescent substance NR668, indicating that these data also are representative for the nanoparticle distribution. Furthermore, immunohistochemistry was used to estimate infiltration of macrophages into the tumor tissue following injection of nanoparticle-encapsulated and free cabazitaxel. The higher infiltration of anti-tumorigenic versus pro-tumorigenic macrophages in tumors treated with the nanoparticles might also contribute to the improved effect obtained with the nanoparticle-encapsulated drug. Tumor infiltration of pro-tumorigenic macrophages was four times lower when using nanoparticles containing cabazitaxel than when using particles without drug, and we speculate that the very good therapeutic efficacy obtained with our cabazitaxel-containing particles may be due to their ability to reduce the level of pro-tumorigenic macrophages in the tumor. In summary, encapsulation of cabazitaxel in poly(2-ethyl-butyl cyanoacrylate) nanoparticles seems promising for treatment of breast cancer.
Cost of care, discharge disposition, and survival of advanced cancer patients (ACP) receiving early inpatient palliative care (PC) compared to standard oncologic care (SOC) without palliative care.
Authors: Christopher Daugherty, Julie Johnson, Stacie K. Levine, Kristen Wroblewski, Bradford Lane, William Dale, Monica Malec, Fay J. Hlubocky
Journal: Journal of Clinical Oncology (2018)

130 Background: PC significantly enhances ACP quality of life, provides symptom control, improves transitions to end-of-life care, and mortality. However, the financial implications, discharge disposition, and survival benefits of early, inpatient PC compared to SOC remains less understood. Methods: Retrospective cohort analysis of ACP receiving either PC or SOC between Jan 2015-Dec 2015 (N=810). ACP cohorts were compared for demographics, costs, disposition, and survival. Financial costs collected included: fixed (overhead expenditures, facility maintenance, hospital property); variable (patient care supplies, diagnostic/therapeutic supplies, medications); operating (fixed, variable, breaking-even costs); direct (labor, materials, commissions, piece-rate wages, manufacturing supplies); indirect (production supervision salaries, quality control, insurance, depreciation). Univariate and multivariate analyses were completed. Results: 468 were admitted to PC and 342 to SOC. In comparison with SOC, PC were more likely to be: younger (61.1±13.2 vs. 62.5±13.0, p=0.02); African American (48% vs. 36%, p=0.0045); female (50% vs. 40%, p=0.005); and have shorter length of inpatient stay (5.7± 4.9 vs. 6.2±6.5, p=0.01). PC had significantly lower costs: direct ($9,478 vs. $10,416, p=0.01); indirect ($9,538 vs. $10,999, p=0.002); fixed ($10,308 vs. $12,076, p=0.001); variable ($8,709 vs. $ 9,339, p=0.02); operating ($19,017 vs. $21,416, p=0.003).Compared with SOC, ACP receiving PC were more likely to be discharged to: home (55% vs.45%, p=0.01); health care facilities (e.g. skilled nursing, inpatient rehabilitation) (36.1% vs. 20%, p=0.04); and hospice (home and inpatient) (7.7% vs. 5.8%, p=0.02). PC had overall greater median survival from the time of discharge (106.8±99.95 vs. 73.8±61.93, p=0.03) compared to SOC. Conclusions: Early PC results in less financial burden and greater cost savings for inpatient ACP including for those who are younger and underserved. These findings provide further evidence for policies arguing that ACP access to routine PC must become a health care priority.
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)
Authors: Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, Guido E. van den Berk, Marjo van Kasteren, Dirk Posthouwer, Anthonius S.M. Dofferhoff, Bart van Hoek, Dewkoemar Ramsoekh, Jelle Koopsen, Janke Schinkel, Eric Florence, Joop E. Arends, Bart J. Rijnders
Journal: Journal of Hepatology (2018)
A randomized controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain.
Authors: Mihir Kamdar, Amanda Jayne Centi, Stephen Agboola, Nils Fischer, Simone Rinaldi, Jacob J. Strand, Lara Traeger, Jennifer S. Temel, Joseph Greer, Areej El-Jawahri, Vicki Jackson, Joseph Kvedar, Kamal Jethwani
Journal: Journal of Clinical Oncology (2019)

11514 Background: Cancer pain is a significant problem that impairs patient quality of life and increases healthcare utilization. ePAL is a smartphone application that utilizes patient-reported outcomes (PROs) and artificial intelligence (AI) to optimize cancer pain management. This randomized controlled trial examined the impact of ePAL on cancer pain severity, attitudes toward cancer pain, and healthcare utilization. Methods: Patients with pain from metastatic solid tumors (n = 112) undergoing treatment in a palliative care clinic were randomized to either a control group (n = 56) that received usual care or an intervention group (n = 56) that received ePAL in addition to usual care for 8 weeks. Measures of pain severity (Brief Pain Inventory), attitudes towards cancer treatment (Barriers Questionnaire II) and anxiety (General Anxiety Disorder-7) were assessed. We used repeated measures mixed modeling to assess change in outcome measures over time. We also conducted a chart review to identify pain-related hospital admissions and emergency department (ED) visits and compared risk between study groups. Results: Pain severity (BPI) and negative attitudes toward cancer treatment (BQ-II) decreased significantly for those assigned to ePAL compared to controls (ß = -0.09, p = 0.034 and ß = -0.037, p = 0.042, respectively). Patients assigned to ePAL reported higher anxiety scores compared to controls (ß = 0.21, p = 0.015). Patients assigned to ePAL had significantly fewer pain-related hospital admissions (n = 4 vs. n = 20, per patient risk ratio 0.31, p = 0.018) and fewer pain-related admissions through the ED (n = 2 vs. n = 14, per patient risk ratio 0.18, p = 0.008) compared to control group. Conclusions: To our knowledge, this is the first mobile app to utilize patient reported outcomes and artificial intelligence to significantly decrease pain scores and pain-related hospitalizations in patients with cancer-related pain. Future directions include examining the efficacy of ePAL in settings with limited access to palliative care.
Risk-Reducing Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Authors: Susan M. Domchek
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Settling the Controversy—Appendectomy as the Criterion for Appendicitis Diagnosis
Authors: Gentian Kristo, Kamal M. F. Itani
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Paper Microfluidics for Cell Analysis
Authors: Jun Ma, Shiqiang Yan, Chunyue Miao, Linmei Li, Weiwei Shi, Xianming Liu, Yong Luo, Tingjiao Liu, Bingcheng Lin, Wenming Wu, Yao Lu
Journal: Advanced Healthcare Materials (2018)

Abstract Paper microfluidics has attracted much attention since its first introduction around one decade ago due to the merits such as low cost, ease of fabrication and operation, portability, and facile integration with other devices. The dominant application for paper microfluidics still lies in point‐of‐care testing (POCT), which holds great promise to provide diagnostic tools to meet the ASSURED criteria. With micro/nanostructures inside, paper substrates provide a natural 3D scaffold to mimic native cellular microenvironments and create excellent biointerfaces for cell analysis applications, such as long‐term 3D cell culture, cell capture/phenotyping, and cell‐related biochemical analysis (small molecules, protein DNA, etc.). This review summarizes cell‐related applications based on various engineered paper microdevices and provides some perspectives for paper microfluidics‐based cell analysis.
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure
Authors: Kelsie E. Oatmen, Michael R. Zile, John C. Burnett, Francis G. Spinale
Journal: JAMA Cardiology (2018)

The standard pharmacotherapy for heart failure (HF), particularly HF with reduced ejection fraction (HFrEF), is primarily through the use of receptor antagonists, notably inhibition of the renin-angiotensin system by either angiotensin-converting enzyme inhibition or angiotensin II receptor blockade (ARB). However, the completed Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial identified that the use of a single molecule (sacubitril/valsartan), which is an ARB and the neutral endopeptidase inhibitor (NEPi) neprilysin, yielded improved clinical outcomes in HFrEF compared with angiotensin-converting enzyme inhibition alone.This review examined specific bioactive signaling pathways that would be potentiated by NEPi and how these would affect key cardiovascular processes relevant to HFrEF. It also addressed potential additive/synergistic effects of ARB. A number of biological signaling pathways that may be potentiated by sacubitril/valsartan were identified, including some novel candidate molecules, which will act in a synergistic manner to favorably alter the natural history of HFrEF.This review identified that activation rather than inhibition of specific receptor pathways provided favorable cardiovascular effects that cannot be achieved by renin-angiotensin system inhibition alone. Thus, an entirely new avenue of translational and clinical research lies ahead in which HF pharmacotherapies will move beyond receptor antagonist strategies.
Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies
Authors: J.A. Fox, D. Langbecker, J. Rosenberg, S. Ekberg
Journal: British Journal of Dermatology (2018)

Recent advances in advanced melanoma therapies are associated with improved survival for some patients. However, how patients with diagnoses of advanced disease and their carers experience this expanding treatment paradigm is not well understood.To explore bereaved carers' accounts of the trajectory of advanced melanoma involving treatment by immune or targeted therapies, to build an understanding of their experiences of care relating to diagnosis and prognosis.A qualitative exploratory design, using methods drawn from grounded theory, was adopted. Analyses drew on in-depth interviews with 20 bereaved carers from three metropolitan melanoma treatment centres in Australia. A flexible interview guide and structured approach to concurrent data collection and analysis were applied.Carers described qualities of the experience, including the shock of diagnosis after a sometimes-innocuous presentation with vague symptoms. They reported an unclear prognosis with complexity arising from interplay between an uncertain disease trajectory and often ambiguous expectations of outcomes of emerging immune and targeted therapies. Uncertainty dominated carers' experiences, increasing the complexity of care planning.Effective communication of an advanced melanoma diagnosis and prognosis is critical. Recognition of the uncertainty inherent in the benefit of immune and targeted therapies in a constructive manner may facilitate more timely and effective care-planning conversations between patients, carers and medical specialists.
Simian malaria in a U.S. traveler - New York, 2008.
Authors: J. G. Ennis, A. E. Teal, A. Habura, S. Madison-Antenucci, J. S. Keithly, P. M. Arguin, J. W. Barnwell, W. E. Collins, S. Mali, L. Slutsker, A. Dasilva, J. Hwang
Journal: MMWR Morbidity and Mortality Weekly Report (2009)
Abstract 16826: Platelet FcγRIIa Polymorphism H131R Associates With Subclinical Atherosclerosis and Increased Platelet Activity in SLE
Authors: Jeffrey S Berger, Robert Clancy, Sara Rasmussen, Janet Nwaukoni, Nicole Allen, Rebecca Dann, Harmony Reynolds, Jill Buyon
Journal: Circulation (2017)

Introduction: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with an elevated risk for premature cardiovascular disease. In addition to their role in atherogenesis, platelets are intercellular regulators of inflammation and immune activation. Platelets express low affinity type 2 receptors (FcγRIIA) whose ligand is the Fc portion of IgG. A single amino acid substitution, H131R, in the extracellular ligand binding domain increases the affinity for IgG and may account for individual variation in platelet activation. Hypothesis: This study addressed the hypothesis that FcyRIIA genotype associates with preclinical atherosclerosis and platelet hyperreactivity. Methods: Genotyping at rs1801274 (allelic discrimination, HWE P=NS) was performed in 179 SLE patients and 30 healthy controls. Carotid ultrasound for plaque, soluble E-selectin, and platelet activity (monocyte- and leukocyte-platelet aggregates (MPA and LPA) and platelet aggregation) were evaluated. Results: Genotyping for FcγRIIA rev...
Before and after major neck surgery
Authors: Stefano Della Villa
Journal: British Journal of Sports Medicine (2018)

I have always loved sport, and I entered into the sports medicine environment for this reason. During my life I have enjoyed swimming, skiing, running, tennis and football, and I have always tried to fit as many of these activities around my family and work commitments as possible.

From a career perspective I was lucky enough to work with the San Francisco 49ers at a young age, before having a wonderful experience working as a sports physician in a Bologna during the next stage of my career. The biggest joy of my professional life was bringing the football medicine community together in recent years via the isokinetic conferences. In short, I love sport and it has played a major part in my life.

I was very fortunate in that for a long time I had never experienced anything close to a serious pathology. I remember feeling surprised when I was first diagnosed with my neck symptoms—how was it possible that an ‘unbreakable man’ like me could have such pain? Eventually I came to humbly understand that I was a normal human being, as vulnerable and as capable of being injured as all the patients that I had seen during my working life.

Following an MRI, I received the diagnosis of triple cervical disc herniation with …
Quantifying the Added Value of Low-Molecular-Weight Heparin to Intermittent Pneumatic Compression for Preventing Venous Thromboembolic Events Under the Risk-Benefit Perspective
Authors: Zachary R. McCaw, Steven Piantadosi, Lee-Jen Wei
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Evaluation of a multi-disciplinary, systematic approach to palliative care for patients undergoing active treatment for head and neck cancer.
Authors: Eleanor Jensen, Deborah Nuccio, Matthew H. Stenmark
Journal: Journal of Clinical Oncology (2018)

91 Background: Patients who receive concurrent chemoradiation therapy for head and neck cancer (H&amp;N CA) commonly experience a range of symptoms, including dysphagia, weight loss, and dehydration, which may impact their treatment and prognosis. Treatment of patients with H&amp;N CA often involves multiple specialties, including Surgery, Medical, and Radiation Oncology, and Palliative Care. In January 2017, Kaiser Permanente Colorado (KPCO) began providing early, integrated palliative care for all H&amp;N CA patients (stages I-IV) starting chemoradiation at a single clinic site. This quality improvement program was subsequently evaluated for ease of implementation and, secondarily, to discern impacts on patient care. Methods: Retrospective chart review was performed for patients undergoing treatment in 2017 for H&amp;N CA with concurrent chemoradiation therapy who also received integrated palliative care (n = 16) compared to standard care patients (n = 32) from 2015-2017. Data on rates of unplanned hospitalizations and feeding tube placement, completion of Medical Durable Power of Attorney (MDPOA) and Edmonton Symptom Assessment Scale (ESAS) were extracted from the electronic health record. Descriptive and inferential statistics were used to review data. Assessment of implementation occurred by interviews with the clinical teams. Results: Implementation of the program required intentional work between departments to define roles and reduce unwanted overlap. Standardized nursing assessments of symptom burden were developed. Patients followed in an integrated fashion had increased MDPOA and ESAS completion (38% vs 6%) and decreased hospital admissions (19% vs 53%) and unplanned PEG tube insertions (13% vs 34%). Differences were statistically significant for hospitalizations (p = 0.022) and ESAS completion (p = 0.006). Conclusions: Development of integrated patient management required intentional inter-department team communication and did not disrupt the clinic environment of any department. Lower hospitalization rates may be related to increased monitoring of symptoms. Based on this experience, the program was expanded to other clinical sites within KPCO.